News Release
Print Page Print Page | E-mail Page E-mail Page | E-mail Alerts E-mail Alerts
Printer Friendly Version View printer-friendly version
<< Back
USANA Health Sciences Reports Net Sales of $233.3 Million; 31% Increase in EPS for Third Quarter 2015
  • Third quarter net sales increased 21.5% to $233.3 million
  • Third quarter EPS increased 30.6% to $1.92
  • Number of active Associates increased 39.2% to 405,000
  • Company increases EPS outlook for 2015

SALT LAKE CITY--(BUSINESS WIRE)--Nov. 3, 2015-- USANA Health Sciences, Inc. (NYSE: USNA) today announced record financial results for its fiscal third quarter ended October 3, 2015.

Financial Performance

For the third quarter of 2015, net sales increased to $233.3 million, up 21.5% compared with $191.9 million in the prior-year period. The increase in net sales was driven by 39.2% growth in the number of active Associates and 15.6% growth in the number of Preferred Customers. Fluctuations in currency exchange rates negatively impacted net sales by $18.3 million year-over-year and $7.3 million on a sequential quarter basis. Third quarter net sales increased 31.1% year-over-year on a constant currency basis.

Net earnings for the third quarter increased by 31.3% to $25.6 million, compared with $19.5 million during the prior-year period. The increase in net earnings was driven by higher net sales, improved gross margins and lower relative selling, general and administrative expense, which were partially offset by higher relative Associate Incentives expense and a higher effective tax rate.

Earnings per diluted share for the third quarter increased 30.6% to $1.92, compared with $1.47 in the prior year period. The increase in earnings per share was attributable to higher net earnings. Weighted average diluted shares outstanding were 13.3 million as of the end of the third quarter of 2015, and were essentially unchanged compared with the prior-year period. During the third quarter of 2015, the Company did not repurchase any shares of common stock. The Company ended the third quarter with $174.2 million in cash and cash equivalents, zero debt and $61.2 million remaining under the current share repurchase authorization.

“We continued to see strong momentum in our business during the third quarter and achieved our fourth consecutive quarter of double-digit sales, earnings and customer growth,” said Dave Wentz, USANA’s Co-CEO. “While currency fluctuations negatively impacted our reported results, we generated strong local currency sales growth in nearly all of our markets. Our results continue to be driven by our strategies for customer growth, which is our highest priority as we seek to improve the overall health and nutrition of our customers around the world.”

Regional Results

Net sales in the Asia Pacific region increased by 29.1% to $168.2 million, despite a negative impact of $11.8 million due to the strengthening of the U.S. dollar. Southeast Asia Pacific incurred 65% of the total impact of currency fluctuations. Sales increased 45.5% in the Greater China region, 3.3% in the Southeast Asia Pacific region, and 16.3% in the North Asia region.

Sales growth in Greater China was driven by strong customer growth in Mainland China, while growth in Southeast Asia Pacific resulted from double-digit customer growth in nearly every market in the region. Finally, sales growth in North Asia was driven by 50% customer growth in South Korea. The number of active Associates in the Asia Pacific region increased by 51.2% year-over-year, and 2.6% sequentially.

Net sales in the Americas/Europe region increased by 5.5% to $65.1 million and were negatively impacted by $6.5 million due to the strengthening of the U.S. dollar. Canada and Mexico each generated double-digit customer and local currency sales growth in the third quarter, compared with the prior year period. Both sales and customer count improved modestly in the U.S.

“Our consistent growth reflects the demand for USANA’s best-in-class products and rewarding business opportunity,” said Kevin Guest, USANA’s Co-CEO. “During the quarter, we held our annual International Convention in Salt Lake City where we celebrated the achievements of our Associates with a record number of attendees. During the fourth quarter, we will officially open Indonesia, our 20th market, and hold our China National Meeting. Mainland China continues to be a key driver of our growth and we anticipate another amazing event with record attendance.”

Outlook

The Company provided the following updated consolidated net sales and earnings per share outlook for 2015:

  • Consolidated net sales between $915 million and $920 million, versus the previous outlook of between $900 million and $920 million
  • Earnings per share between $7.25 and $7.35, versus the previous outlook of between $6.90 and $7.20

Conference Call

The Company has posted the “Management Commentary, Results and Outlook” document on the Company’s website (www.usanahealthsciences.com) under the “Investor Relations” section of the site. USANA will hold a conference call and webcast to discuss today’s announcement with investors on Wednesday, November 4, 2015 at 11:00 AM Eastern Time. Investors may listen to the call by accessing USANA’s website at http://www.usanahealthsciences.com. The call will consist of brief opening remarks by the Company’s management team, before moving directly into questions and answers.

About USANA

USANA develops and manufactures high-quality nutritional supplements, healthy foods and personal care products that are sold directly to Associates and Preferred Customers throughout the United States, Canada, Australia, New Zealand, Hong Kong, China, Japan, Taiwan, South Korea, Singapore, Mexico, Malaysia, the Philippines, the Netherlands, the United Kingdom, Thailand, France, Belgium and Colombia. More information on USANA can be found at http://www.usanahealthsciences.com.

Safe Harbor

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. Our actual results could differ materially from those projected in these forward-looking statements, which involve a number of risks and uncertainties, including global economic conditions generally, reliance upon our network of independent Associates, the governmental regulation of our products, manufacturing and marketing risks, adverse publicity risks, and risks associated with our international expansion. The contents of this release should be considered in conjunction with the risk factors, warnings, and cautionary statements that are contained in our most recent filings with the Securities and Exchange Commission.

                   
USANA Health Sciences, Inc.
Consolidated Statements of Earnings
(In thousands, except per share data)
(Unaudited)
 
Quarter Ended Nine Months Ended
27-Sep-14 3-Oct-15 27-Sep-14 3-Oct-15
 
Net sales $ 191,944 $ 233,292 $ 562,601 $ 685,914
Cost of sales   34,585     41,048   103,278   119,501
Gross profit 157,359 192,244 459,323 566,413
 
Operating expenses
Associate incentives 82,605 101,521 242,577 304,751
Selling, general and administrative   45,499     52,757   133,282   155,137
 
Earnings from operations 29,255 37,966 83,464 106,525
 
Other income (expense)   (297 )   441   125   523
Earnings before income taxes 28,958 38,407 83,589 107,048
 
Income taxes   9,460     12,798   28,253   36,343
 
NET EARNINGS $ 19,498   $ 25,609 $ 55,336 $ 70,705
 
 
Earnings per share - diluted $ 1.47 $ 1.92 $ 3.96 $ 5.35
Weighted average shares outstanding - diluted 13,263 13,317 13,964 13,209
 
 
 
USANA Health Sciences, Inc.
Consolidated Balance Sheets
(In thousands)
(Unaudited)
 
As of As of
ASSETS 3-Jan-15 3-Oct-15
Current Assets
Cash and cash equivalents $ 111,126 $ 174,195
Inventories 45,248 61,580
Prepaid expenses and other current assets   34,553     34,049
Total current assets 190,927 269,824
 
Property and equipment, net 71,164 78,525
Goodwill 17,941 17,675
Intangible assets, net 40,952 39,506
Deferred income taxes 5,933 8,352
Other assets   23,667     25,046
Total assets $ 350,584   $ 438,928
 
 
LIABILITIES AND STOCKHOLDERS' EQUITY
Current Liabilities
Accounts payable $ 7,779 $ 9,498
Other current liabilities   100,926     104,967
Total current liabilities 108,705 114,465
 
Other long-term liabilities 1,114 1,044
Deferred income taxes 10,601 10,030
 
Stockholders' equity   230,164     313,389
Total liabilities and stockholders' equity $ 350,584   $ 438,928
 

                   
USANA Health Sciences, Inc.
Sales by Region
(Unaudited)
(In thousands)
           
Quarter Ended
27-Sep-14 3-Oct-15 Change from prior year Change on constant currency basis

Region

 
Asia Pacific
 
Greater China $ 77,206 40.2 % $ 112,323 48.1 % 35,117 45.5 % 2,638 48.9 %
 
Southeast Asia Pacific 44,488 23.2 % 45,936 19.7 % 1,448 3.3 % 7,735 20.6 %
 
North Asia   8,527 4.4 %   9,920 4.3 % 1,393 16.3 % 1,444 33.3 %
 
Asia Pacific Total 130,221 67.8 % 168,179 72.1 % 37,958 29.1 % 11,817 38.2 %
 
Americas and Europe   61,723 32.2 %   65,113 27.9 % 3,390 5.5 % 6,483 16.0 %
 
Total $ 191,944 100.0 % $ 233,292 100.0 % 41,348 21.5 % 18,300 31.1 %
 
 
Active Associates by Region (1)
(Unaudited)
 
As of
27-Sep-14 3-Oct-15

Region

 
Asia Pacific
 
Greater China 129,000 44.3 % 218,000 53.8 %
 
Southeast Asia Pacific 70,000 24.1 % 85,000 21.0 %
 
North Asia   10,000 3.4 %   13,000 3.2 %
 
Asia Pacific Total 209,000 71.8 % 316,000 78.0 %
 
Americas and Europe   82,000 28.2 %   89,000 22.0 %
Total   291,000 100.0 %   405,000 100.0 %
 
(1) Associates are independent distributors of our products who also purchase our products for their personal use. We only count as active those Associates who have purchased from us any time during the most recent three-month period, either for personal use or for resale.
 
 
Active Preferred Customers by Region (2)
(Unaudited)
 
As of
27-Sep-14 3-Oct-15

Region

 
Asia Pacific
 
Greater China 3,000 3.9 % 4,000 4.5 %
 
Southeast Asia Pacific 11,000 14.3 % 13,000 14.6 %
 
North Asia   6,000 7.8 %   9,000 10.1 %
 
Asia Pacific Total 20,000 26.0 % 26,000 29.2 %
 
Americas and Europe   57,000 74.0 %   63,000 70.8 %
Total   77,000 100.0 %   89,000 100.0 %
 
 
(2) Preferred Customers purchase our products strictly for their personal use and are not permitted to resell or to distribute the products. We only count as active those Preferred Customers who have purchased from us any time during the most recent three-month period.

Source: USANA Health Sciences, Inc.

USANA Health Sciences, Inc.
Investors contact:
Patrique Richards, 801-954-7961
Investor Relations
investor.relations@us.usana.com
or
Media contact:
Dan Macuga, 801-954-7280
Public Relations

USANA Health Sciences is known for manufacturing the highest quality products backed by a potency guarantee. To ensure you and your family are receiving genuine world-class USANA products, purchase them only through your independent USANA Associate or www.usana.com.
What's Up UsanaFacebookTwitterInstagramPintrestYouTubeGoogle PlusLinkedin
dsa.orgnsf.orgTrue Health FoundationTeam Usanawtatour.combbb.org